Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.5.1.15 extracted from

  • Zano, S.; Malik, R.; Szucs, S.; Matalon, R.; Viola, R.E.
    Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease (2011), Mol. Genet. Metab., 102, 176-180.
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.5.1.15

Application

Application Comment Organism
medicine mutations in the aspartoacylase aspA gene are implicated as the cause of Canavan Disease Homo sapiens

Cloned(Commentary)

Cloned (Comment) Organism
expressed in Pichia pastoris Homo sapiens

General Stability

General Stability Organism
PEGylated forms of aspartoacylase (modified with PEG of 2 kDa, 5 kDa, 10 kDa, 20 kDa or 40 kDa) show similar activities to that of the native enzyme. The activity of PEGylated enzyme samples is monitored for 72 hours without observing a substantial loss in activity Homo sapiens

Molecular Weight [Da]

Molecular Weight [Da] Molecular Weight Maximum [Da] Comment Organism
35000
-
 x * 35000, SDS-PAGE Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Purification (Commentary)

Purification (Comment) Organism
nickel Sepharose column chromatography and Source 15Q column chromatography Homo sapiens

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
N-acetyl-L-aspartate + H2O
-
 Homo sapiens L-aspartate + acetate
-
 ?

Subunits

Subunits Comment Organism
? x * 35000, SDS-PAGE Homo sapiens

Synonyms

Synonyms Comment Organism
ASPA
-
 Homo sapiens